Bingfei Yu, PhD Parker Bridge Fellow (in partnership with the V Foundation for Cancer Research) Biography In 2018, Bingfei joined the lab of Howard Chang, MD, PhD, at Stanford University as a postdoctoral researcher. She identified an essential role of female-specific long non-coding RNA XIST in maintaining X-inactivation and restraining atypical B cell formation. This work begins to explain why females are more likely to develop autoimmune diseases. Recently, she has been developing a viral display and delivery platform. Combined with single-cell genomics, this platform empowers researchers to decode ligand-receptor communications and links such communication to cellular state/behavior at the single-cell level. She will continue to develop and apply this technology in the tumor immunology field to understand how intercellular communication guides the immune system to eradicate tumors. She is a Parker Bridge Fellow and a postdoctoral researcher at Stanford University School of Medicine, where she works on targeting mechanisms of T cells and other immune cells to clear cancer cells from the body. Bingfei is developing techniques to decode and rewire the human immune system so that personalized cancer therapy can be within reach for every patient. She received her PhD in Immunology from the University of California, San Diego, where she studied the differentiation and function of CD8+ T cells in killing pathogen-infected cells and cancer cells. Education & Training 2018-present: Postdoctoral Researcher, Stanford University 2018: University of California, San Diego, PhD, Immunology 2012: Xiamen University (China), MS, Biochemistry and Molecular Biology 2009: Xiamen University (China), BS, Biology Awards & Honors 2022: Parker Bridge Fellow 2019: Dean's Postdoctoral Fellowship, Stanford University School of Medicine 2017: Biology Founding Faculty Award for Graduate Excellence, University of California, San Diego 2016: Marguerite Vogt Award, University of California, San Diego